Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024

Skyhawk Therapeutics announced positive Phase 1 trial results for SKY-0515, showing a 72% reduction in HTT mRNA at a 9mg dose, well-tolerated in healthy volunteers. Part C, enrolling Huntington's patients, expects topline data by Q2 2025. SKY-0515 targets HTT and PMS1 proteins, key in Huntington's disease.